Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Glioblastoma Institute
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Brain Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Brain Cancer

Journal Scan / Research · December 15, 2021

ERK1/2 Phosphorylation Predicts Survival After Anti–PD-1 ICI in Recurrent Glioblastoma

Nature Cancer

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

L. Gonzalez Castro MD, PhD

Patrick Wen MD

Nature Cancer
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma
Nat Cancer 2021 Nov 29;[EPub Ahead of Print], VA Arrieta, AX Chen, JR Kane, et al

Further Reading

Recently Updated